A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

• Published in: Movement disorders Vol. 31; no. 9; pp. 1373 - 1380
• Main Authors: Tison, François, Keywood, Charlotte, Wakefield, Mark, Durif, Franck, Corvol, Jean-Christophe, Eggert, Karla, Lew, Mark, Isaacson, Stuart, Bezard, Erwan, Poli, Sonia-Maria, Goetz, Christopher G., Trenkwalder, Claudia, Rascol, Olivier
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.09.2016; Wiley Subscription Services, Inc; Wiley
• Subjects: Aged; dipraglurant; Dopamine Agents - adverse effects; Double-Blind Method; Dyskinesia, Drug-Induced - drug therapy; Female; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - pharmacology; Levodopa - adverse effects; levodopa-induced dyskinesia; Life Sciences; Male; mGluR5 antagonist; Middle Aged; Movement disorders; Outcome Assessment (Health Care); Parkinson Disease - drug therapy; Parkinson's disease; phase 2A; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - pharmacology; Receptor, Metabotropic Glutamate 5 - antagonists & inhibitors; phase 2A; dipraglurant; levodopa-induced dyskinesia; Parkinson's disease; mGluR5 antagonist
• ISSN: 0885-3185; 1531-8257; 1531-8257
• DOI: 10.1002/mds.26659

ABSTRACT Background The metabotropic glutamate receptor 5‐negative allosteric modulator dipraglurant reduces levodopa‐induced dyskinesia in the MPTP‐macaque model. The objective of this study was to assess the safety, tolerability (primary objective), and efficacy (secondary objective) of dipraglura...